The Zhitong Finance App learned that Lyon released a research report saying that maintaining the “buy” rating of Ali Health (00241), it is more optimistic about growth and profit prospects, raised the revenue forecast for the current fiscal year and 8% each, and raised the adjusted net profit forecast for the same period by 9% each. The target price was raised from HK$4.1 to HK$4.5.

According to the report, the company's performance for the second half of fiscal year 2024 far surpassed the bank's expectations under a high base, and the increase in efficiency significantly boosted profit margins. Alibaba Health is more proactive in expanding its own business, while attracting all merchants to increase advertising investment through exclusive supply, new products and operational efforts.